NCT06851442 - Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Breast Cancer

Interventions

DRUG

TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists.

Trial Locations (17)

31800

NOT_YET_RECRUITING

Taizhou Central Hospital (Taizhou University Affiliated Hospital), Taizhou

110000

NOT_YET_RECRUITING

Liaoning Cancer Hospital, Shenyang

150000

RECRUITING

Harbin Medical University Cancer, Harbin

233000

NOT_YET_RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

300202

NOT_YET_RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

315000

NOT_YET_RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

350009

NOT_YET_RECRUITING

Fuzhou First General Hospital, Fuzhou

362000

NOT_YET_RECRUITING

Quanzhou First Hospital, Quanzhou

425002

NOT_YET_RECRUITING

Yongzhou Central Hospital, Yongzhou

430071

NOT_YET_RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

514000

NOT_YET_RECRUITING

Meizhou peoples Hospital, Meizhou

550001

NOT_YET_RECRUITING

Guizhou Medical University Affiliated Cancer Hospital Co., Ltd, Guiyang

550002

NOT_YET_RECRUITING

Guizhou Provincial People's Hospital, Guiyang

710061

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

830000

NOT_YET_RECRUITING

Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi

030000

NOT_YET_RECRUITING

Shanxi Cancer Hospital, Taiyuan